The Journal of Thoracic and Cardiovascular Surgery
Volume 138, Issue 3 , Pages 619-624 , September 2009

Extrapleural pneumonectomy for malignant pleural mesothelioma: Outcomes of treatment and prognostic factors

  • Tristan D. Yan, BSc(Med), MBBS, PhD

      Affiliations

    • The University of Sydney, Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney, Australia
    • The Baird Institute for Applied Heart and Lung Surgical, Sydney, Australia
    • ,
  • Michael Boyer, MBBS, PhD, FRACP

      Affiliations

    • Department of Medical Oncology, Sydney Cancer Center, Royal Prince Alfred Hospital, Sydney, Australia
    • ,
  • Mo Mo Tin, MBBS

      Affiliations

    • Department of Radiation Oncology, Sydney Cancer Center, Royal Prince Alfred Hospital, Sydney, Australia
    • ,
  • Daniel Wong, MBBS

      Affiliations

    • Department of Radiation Oncology, Sydney Cancer Center, Royal Prince Alfred Hospital, Sydney, Australia
    • ,
  • Catherine Kennedy, RM, RA

      Affiliations

    • The University of Sydney, Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney, Australia
    • The Baird Institute for Applied Heart and Lung Surgical, Sydney, Australia
    • ,
  • Jocelyn McLean, RN, MN

      Affiliations

    • The University of Sydney, Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney, Australia
    • The Baird Institute for Applied Heart and Lung Surgical, Sydney, Australia
    • ,
  • Paul G. Bannon, MBBS, PhD, FRACS

      Affiliations

    • The University of Sydney, Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney, Australia
    • The Baird Institute for Applied Heart and Lung Surgical, Sydney, Australia
    • ,
  • Brian C. McCaughan, MBBS, FRACS

      Affiliations

    • The University of Sydney, Department of Cardiothoracic Surgery, Royal Prince Alfred Hospital, Sydney, Australia
    • The Baird Institute for Applied Heart and Lung Surgical, Sydney, Australia
    • Corresponding Author InformationAddress for reprints: Brian C. McCaughan, MBBS, FRACS, 304/100 Carillon Avenue, Newtown, NSW 2042, Australia.

Received 26 August 2008 ,Revised 2 December 2008 ,Accepted 28 December 2008.

References 

  1. Butchart E, Ascroft T, Barnsley W, et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Thorax. 1976;31:15–24
  2. Branscheid D, Krysa S, Bauer E, et al. Diagnostic and therapeutic strategy in malignant pleural mesothelioma. Eur J Cardiothorac Surg. 1991;5:466–473
  3. Ruffie P, Feld R, Cormier M, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol. 1989;7:1157–1168
  4. Brancatisano R, Joseph M, McCaughan B. Pleurectomy for mesothelioma. Med J Aust. 1991;154:455–460
  5. Rusch V, Piantadosi S, Holmes E. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1991;102:1–9
  6. Sugarbaker D, Heher E, Lee T, et al. Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1991;102:10–15
  7. Sugarbaker D, Norberto J. Multimodality management of malignant pleural mesothelioma. Chest. 1998;113:61–65
  8. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122:788–795
  9. Yajnik S, Rosenzweig KE, Mychalczak B, et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003;56:1319–1326
  10. Sugarbaker DJ. Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol. 2006;1:175–176
  11. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol. 2007;2:957–965
  12. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004;128:138–146
  13. de Perrot M, McRae K, Anraku M, et al. Risk factors for major complications after extrapleural pneumonectomy for malignant pleural mesothelioma. Ann Thorac Surg. 2008;85:1206–1210
  14. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644
  15. Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006;24:1443–1448
  16. Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008;19:370–373
  17. Rusch V, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1996;111:815–826
  18. Flores R, Routledge T, Seshan VE, et al. The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: implications for revision of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg. 2008;136:605–610
  19. Christensen B, Godleski J, Roelofs C, et al. Asbestos burden predicts survival in pleural mesothelioma. Environ Health Perspect. 2008;116:723–726
  20. Sugarbaker D, Flores R, Jaklitsch M, et al. Resection margins, extrapleural nodal status and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–65
  21. Edwards JG, Stewart DJ, Martin-Ucar A, et al. The pattern of lymph node involvement influences outcome after extrapleural pneumonectomy for malignant mesothelioma. J Thorac Cardiovasc Surg. 2006;131:981–987
  22. Flores RM. Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience. Lung Cancer. 2005;49(Suppl 1):S71–S74
  23. Rea F, Marulli G, Bortolotti L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer. 2007;57:89–95
  24. Maziak DE, Gagliardi A, Haynes AE, et al. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer. 2005;48:157–169
  25. Muers M, Stephens R, Fisher P, et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008;371:1685–1694
  26. Riquet M, Assouad J, Bagab P, et al. Skip mediastinal lymph node metastasis and lung cancer: a particular N2 subgroup with a better prognosis. Ann Thorac Surg. 2005;79:225–233
  27. de Perrot M, Uy K, Anraku M, et al. Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2007;133:111–116

PII: S0022-5223(09)00148-2

doi: 10.1016/j.jtcvs.2008.12.045

The Journal of Thoracic and Cardiovascular Surgery
Volume 138, Issue 3 , Pages 619-624 , September 2009

Article Tools

* Image Usage & Resolution